RecruitingPhase 2NCT07085234

Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The First Affiliated Hospital of Xiamen University
Intervention
Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen(drug)
Enrollment
30 target
Eligibility
18-65 years · All sexes
Timeline
20252029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07085234 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials